Vivos Therapeutics (VVOS) Assets Average (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Assets Average data on file, last reported at $25.1 million in Q1 2026.

• On a quarterly basis, Assets Average rose 88.94% year-over-year to $25.1 million in Q1 2026; TTM through Mar 2026 was $25.1 million, a 88.94% increase from a year earlier, with the FY2025 full-year figure at $20.2 million, up 55.44% from the prior year.
• Assets Average for Q1 2026 stood at $25.1 million, down from $25.4 million in the prior quarter.
• Over the last five years, Assets Average for VVOS reached as high as $31.6 million in Q1 2022 and fell as low as $10.5 million in Q4 2023.
• Historically, Assets Average has averaged $18.5 million across 5 years, with a median of $15.6 million in 2024.
• Across the five-year window, Assets Average tumbled 57.01% in 2022 and surged 88.94% in 2026, its largest moves.
• Year by year, Assets Average stood at $16.1 million in 2022, then plunged by 34.47% to $10.5 million in 2023, then soared by 45.54% to $15.3 million in 2024, then soared by 65.83% to $25.4 million in 2025, then retreated by 1.18% to $25.1 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $25.1 million in Q1 2026, $25.4 million in Q4 2025, and $25.8 million in Q3 2025.